Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

InDex's UC therapy heading for Phase III
InDex Pharmaceuticals Holding AB (SSE:INDEX) is planning Phase III testing of cobitolimod after the DNA-based immunomodulatory sequence (DIMS) therapy

Read the full 259 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE